Condition: Pleural Mesotheliomas · Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Multicentre, open-label, single arm phase II study for patients with PM previously treated by immunotherapy and standard chemotherapy. 38 patients will be given second or third-line treatment with ivonescimab 20mg/kg every 3 weeks. An estimated 38 patients will be enrolled in approximately 20 centres. Patients will be treated for a maximum of 2 years, until disease progression, unacceptable toxicity, withdrawal of consent or another discontinuation criterion is met. The null hypothesis is disease control rate (DCR) at 12 weeks ≤ 30%. The alternative hypothesis is DCR ≥ 55% at 12 weeks.
This description comes directly from the study's public registry record.
IFCT · +33 156811046 · contact@ifct.fr
Always discuss trial participation with your own doctor first.
| Besançon - CHU | Besançon, France | Recruiting |
| Brest - CHU | Brest, France | Recruiting |
| Caen - CHU | Caen, France | Recruiting |
| Clermont-Ferrand - Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| Créteil - CHI | Créteil, France | Recruiting |
| Grenoble - CHU | Grenoble, France | Recruiting |
| Le Mans - CHG | Le Mans, France | Recruiting |
| Lille - CHU | Lille, France | Recruiting |
| Marseille - APHM | Marseille, France | Recruiting |
| Montpellier - CHU | Montpellier, France | Recruiting |
| Mulhouse - GHRMSA | Mulhouse, France | Recruiting |
| Nantes - Hôpital Laennec | Nantes, France | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06840834